A Phase I Study To Evaluate The Safety, Tolerability and Pharmacokinetics Of BH009 In Patients With Advanced Head And Neck Squamous (Non-nasopharyngeal) And Ovarian Cancer
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Docetaxel (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Ovarian cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Beihai Biotech
- 04 Jun 2024 Interim results (Up to January 2024, n=11) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 05 Feb 2024 New trial record